Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs: A comprehensive review on their mode of action, treatment of abuse and intoxication

Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs: A Comprehensive Review on their Mode of Action, Treatment of Abuse and Intoxication

Volumn , Issue , 2009, Pages 1-300

  Freye, Enno ^a   Levy, Joseph V ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b University of the Pacifc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84900933944     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-90-481-2448-0     Document Type: Book

References (439)

1. Stocker S. Cocaine abuse may lead to strokes and mental deficits. NIDA Notes. 1998;13:10-2.
2. Sturgess R. Freud, Sherlock Holmes and Coca-Cola - the cocaine connection. Pharmacol J. 2000;265:915-7.
3. Wilson LD, Jeromin G, Shelat C, Huettl B. Tolerance develops to the sympathomimetic but not the local anesthetic effects of cocaine. J Toxicol Clin Toxicol. 2000;38:719-27.
4. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther. 1979;25:464-8.
5. Zhang JY, Foltz RL. Cocaine metabolism in man: identification of four previously unreported cocaine metabolites in human urine. J Anal Toxicol. 1990;14:201-5.
6. Warner A, Norman AB. Mechanism pf cocain hydrolysis and metabolism in vitro and in vivo: a clarification. Ther Drug Monit. 2000;22:266-70.
7. Matsubara K, Kagawa M, Fukui Y. In vivo and in vitro studies on cocaine metabolism: ecgonine methyl ester as a major metabolite of cocaine. Forensic Sci Int. 1984;26:169-80.
8. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary excretion after different routes of administration. Ther Drug Monit. 1098;20:556-60.
9. Harris DS, Everhart ET, Mendelson J, Jones RT. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug Alcohol Depend. 2003;72:169-82.
10. Wilson LD, Henning RJ, Suttheimer C, Lavins E, Balray E, Earl S. Cocaetylene cause dose dependent reductions in cardiac function in anesthetized dogs. J Cardiovasc Pharmacol. 1995;26:965-73.
11. Xu Y, Crumb WJ, Clarkson CW. Cocaethylene, a metabolite of cocaine and ethanol, is a potent blocker of cardiac sodium channels. J Pharmacol Expt Ther. 1994;271:319-25.
12. Cami J, Farré M, González ML, Segura J, de la Torre R. Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Dev Alcohol. 1998;14:437-55.
13. Clapp L, Martin B, Beresford TP. Sublingual cocaine - Novel recurrence of an ancient practice. Clin Neuropharmacol. 2004;27:93-4.
14. Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007;369:1047-53.
15. Goodman LS, Gilman A, Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill; 2006.
16. Abbott A. Neurobiological perspectives on drugs of abuse. TIPS. 1992;13:169.
17. Ramsey NF, van Ree JM. Reward and abuse of opiates. Pharmacol Toxicol. 1992;71(2):81-94.
18. Jaffe JH, Martin WR. Opioid Analgesics and Antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill; 1993. pp. 485-531.
19. Gay GR. Clinical management of acute and chronic cocaine poisoning. Ann Emerg Med. 1982;11:562-72.
20. Rapport RT, Gay GR, Inaba D. Propanolol: a specific antagonist to cocaine. Clin Toxicol. 1977;10:265-71.
21. Wetli CV, Fishbain DA. Cocaine-induced psychosis and sudden death in recreational cocaine users. J Forensic Sci. 1985;30:873-80.
22. Henning RJ, Wilson LD. Cocaethylene is as cardiotoxic as cocaine but is less toxic than cocaine plus ethanol. Life Sci. 1996;59:615-27.
23. Fowler JS, Volkow ND, Logan J, McGregor RR, Wang GF, Wolf AP. [11C]cocaine phrmaciokinertics in human brain and heart. Synapse. 1992;12:228-35.
24. Cami J, Farré M, González ML, Segura J, de la Torre R. Cocaine metabolism in humans after use of alcohol. Clinical and research implications. Recent Dev Alcohol. 1998;14:437-55.
25. Landry MJ. An overview of cocethylene, an alcohol-derived psychoactive, cocaine metabolite. J Psychoactive Drugs. 1992;24:273-6.
26. Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med. 1990;88:325-31.
27. Om A. Cardiovascular complications of cocaine. Am J Med Sci. 1992;303:333-9.
28. Levis JT, Garmel GM. Cocaine-associated chest pain. Emerg Med Clin North Am. 2005;23:1083-103.
29. Hollander JE, Henry TD. Evaluation and management of the patient who has cocaine-associated chest pain. Cardiol Clin. 2006;24:103-14.
30. Eichhorn EJ, Peacock E, Grayburn PA, et al. Chronic cocaine abuse is associated with accelerated atherosclerosis in human coronary arteries. J Am Coll Cardiol. 1992;19:105A.
31. Mouhaffel AH, Madu EC, Satmary WA, Fraker TD. Cardiovascular complications of cocaine. Chest. 1995;107:1426-34.
32. Levis JT, Garmel GM. Cocaine-associated chest pain. Emerg Med Clin North Am. 2005;23:1083-103.
33. Hollander JE, Hoffman RS, Gennis P, et al. Prospective multicenter evaluation of cocaineassociated chest pain. Acad Emerg Med. 1994;1:330-9.
34. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50:e1-e157.
35. Brogan WC, Lange RA, Kim AS, et al. Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. J Am Coll Cardiol. 1991;18:581-6.
36. Hollander JE, Hoffman RS, Gennis P, et al. Nitroglycerin in the treatment of cocaine associated chest pain-clinical safety and efficacy. J Toxicol Clin Toxicol. 1994;32:243-56.
37. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267-72.
38. Honderick T, Williams D, Seaberg D, Wears R. A prospective, randomized, controlled trial of benzodiazepines and nitroglycerine or nitroglycerine alone in the treatment of cocaine-associated acute coronary syndromes. Am J Emerg Med. 2003;21:39-42.
39. Baumann BM, Perrone J, Hornig SE, et al. Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. Acad Emerg Med. 2000;7:878-85.
40. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Arch Intern Med. 1990;112:897-903.
41. Hollander JE, Henry TD. Evaluation and management of the patient who has cocaine-associated chest pain. Cardiol Clin. 2006;24:103-14.
42. Hollander JE, Carter WA, Hoffman RS. Use of phentolamine for cocaine-induced myocardial ischemia. N Engl J Med. 1992;327:361.
43. Hollander JE, Hoffman RS, Gennis P, Fairweather P, Feldman JA, Fish SS, et al. Cocaineassociated chest pain: one year follow-up. Acad Emerg Med. 1995;2:179-84.
44. Hollander JE, Thode HC, Hoffman RS. Chest discomfort, cocaine and tobacco. Acad Emerg Med. 1995;2:238.
45. Welch RD, Todd K, Krause GS. Incidence of cocaineassociated rhabdomyolysis. Ann Emerg Med. 1991;20:154-7.
46. Green R, Kelly KM, Gabrielson T, Levine SR, Vanderzant C. Multiple intracerebral hemorrhages after smoking "crack" cocaine. Stroke. 1990;21:957-62.
47. Levine SR, Brust JCM, Futrell N, Ho KL, Blake D, Millikan CH, et al. Cerebrovascular complications of the use of the "crack" form of alkaloidal cocaine. N Engl J Med. 1990;323:699-704.
48. Westover AN, McBride S, Haley R. Stroke in young adults who abuse amphetamines or cocaine. A population-based study of hospitalized patients. Arch Gen Psychiatry. 2007;64:495-592.
49. Schindler CW. Cocaine and cardiovascular toxicity. Addict Biol. 1996;1:31-47.
50. Karch SB, Billingham ME. The pathology and etiology of cocaine-induced heart disease. Arch Pathol Lab Med. 1988;112:225-30.
51. Lange RA, Cigarro RG, Yancy CWJ, Willard JE, Pompa JJ, Sills MN, et al. Cocaine induced coronary artery vasonstriction. N Eng J Med. 1989;321:1557-62.
52. Robertson MW, Leslie CA, Bennett JPJ. Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res. 1991;538:337-9.
53. Neugebauer V, Zinebi F, Russell R, Gallagher JP, Shinnick-Gallagher P. Cocaine and kindling alter the sensitivity of group II and III metabotropic glutamate receptors in the central amygdala. J Neurophysiol. 2000;84:759-70.
54. Marley RJ, Gioldberg SR. Pharmacogenetic assessment of the effects of carbamazepine on cocaine-kindled and cocaine-induced seizures. Brain Res. 1992;579:43-9.
55. Iccocioppo R, Sanna PP, Weiss F. Cocaine predictive stimulus induces drug seeking behavioral and neural actions in limbic brain regions after multiple months of abstinence. Proc Natl Acad Sci USA. 2001;98:1976-81.
56. Lidow MS, Song ZM. Primates exposed to cocaine in utero display reduced density and number of cerebral cortical neurons. J Comp Neurol. 2001;435:263-75.
57. Lidow MS, Song ZM. Effect of cocaine on cell proliferation in the cerebral wall of monkey fetuses. Cereb Cortex. 2001;11:545-51.
58. Kosofsky BE, Hyman SE. No time for complacency: the fetal brain on drugs. J Comp Neurol. 2001;435:259-62.
59. Smith LM, Qwesbi N, Renslo R, Sinow RM. Prenatal cocaine exposure and cranial sonographic findings in preterm infants. J Clin Ultrasound. 2001;29:72-7.
60. Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001;285:1613-25.
61. Rawson RA, Mc Cann MJ, Hasson AJ, Ling W. Addiction pharmacotherapy 2000: new options, new challenges. J Psychoactive Drugs. 2000;321:371-8.
62. Carrera MRA, Ashley JA, Wirsching P, Koob GF, Janda KD. A second generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA. 2001;98:1988-91.
63. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Medi Chem Lett. 2001;11:87-90.
64. Hayashi T, Su TP. Regulating ankyrin dynamics: roles of sigma 1 receptors. Proc Natl Acad Sci USA. 2001;98:491-6.
65. Schneider-Helmert D, Spinweber CL. Evaluation of L-tryptophan for treatment of insomnia: a review. Psychopharmacology. 1986;89:1-7.
66. Hartmann E. Effects of L-tryptophan on sleepiness and on sleep. J Psychiatr Res. 1982;17:107-13.
67. Lam RW, Levitan RD, Tam EM, Yatham LN, Lamoureux S, Zis AP. L-tryptophan augmentation of light therapy in patients with seasonal affective disorder. Can J Psychiatr. 1997;42:302-6.
68. Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. J Psychiatr Nuerosci. 2000;25:337-46.
69. Meyers S. Use of neurotransmitter precursors for treatment of depression. Alternat Med Rev. 2000;5:64-71.
70. Turner EH, Loftis JM, Blackwell AD. Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther. 2006;109:325-38.
71. Chinevere TD, Sawyer RD, Creer AR, Conlee RK, Parcell AC. Effects of L-tyrosine and carbohydrate ingestion on endurance exercise performance. J Appl Physiol. 2002;93:1590-7.
72. Strÿder HK, Hollmann W, Platen P, Donike M, Gotzmann A, Weber K. Influence of paroxetine, branched-chain amino acids and tyrosine on neuroendocrine system responses and fatigue in humans. Horm Metab Res. 1998;30:188-94.
73. Thomas JR, Lockwood PA, Singh A, Deuster PA. Tyrosine improves working memory in a multitasking environment. Biochem Behav. 1999;64:495-500.
74. Deijen JB, Orlebeke JF. Effect of tyrosine on cognitive function and blood pressure under stress. Brain Res Bull. 1994;33:319-23.
75. Oliveto AH, Feingold A, Schottenfeld R, Jatlow P, Kosten TR. Desipramine in opioiddependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry. 1999;56:812-20.
76. Sherer MA, Kumor KM, Jaffe JH. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res. 1989;27:117-35.
77. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: patterns of drug choice. J Ner Ment Dis. 1987;175:641-52.
78. Tennant FS, Sagherian AA. Double blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch Intern Med. 1987;147:109-12.
79. Grabowski J, Schmitz J, Roache JD, Rhoades H, Elk R, Creson DL, editors. Methylphenidate (MP) for initial treatment of cocaine dependence and a model for medication evaluation. Problems of Drug Dependence Proceedings of the 55th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc; 1993; Washington, DC: NIH Pub. No. 94-3749. Supt. of Docs., US Govt. Print. Off. 1994.
80. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of ?-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse. 2005;55:122-5.
81. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. A randomized placebocontrolled trial. Arch Gen Psychiatry. 2004;61:264-72.
82. Romach MK, Glue P, Kampman K, et al. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry. 1999;56:1101-6.
83. Marx J. How stimulant drugs may calm hyperactivity. Science. 1999;283:306-9.
84. Conrad KL, Tseng KY, Uejima KL, Reimers JM, Heng L-J, Shaham Y, et al. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature. 2008;454:118-21.
85. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76:1169-1174.
86. Nagai N. Kanyaku maou seibun kenkyuu seiseki (zoku). Yakugaku Zashi. 1893;13:801.
87. Müller-Bonn H. Pervitin, ein neues Analepticum. Med Welt. 1939;39:1315-1317.
88. Pellmont B. Vergleichende Untersuchungen über die Wirkungen von Coralin, Coffein und Pervitin auf psychsche und physische Leistung des ermüdeten und nicht-ermüdeten Menschen. Naunyn-Schmiedebergs Arch Exp Pathol Pharmacol. 1942;199:274-291.
89. Doyle D. Hitler's medical care. J Roy Coll Phys Edinburgh. 2005;35:75-82.
90. Kemper WR. Pervitin - Die Endsiegdroge ? Wach und leistungsstark durch Metamphetamin. In: Peier W, editor. Nazis on Speed - Drogen im 3 Reich. Löhrbach: Werner Pieper & The Grüne Kraft 1989. pp. 122-133.
91. Tamura M. Japan: stimulant epidemics past and present. In: Crime OoDa, editor. Geneva: United Nations Bulletin on Narcotics. 1989;41(1 and 2):83-93.
92. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414-9418.
93. Bennett B, Hollingswort HC, Martin R, Harp J. Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998;582:219-227.
94. Marx J. How stimulant drugs may calm hyperactivity. Science. 1999;283:306-309.
95. Garris PA, Kilpatrick M, Bunin MA, Michae lD, Walker QD, Wightman RM. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation [letter]. Nature. 1999;398:67-69.
96. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White J. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100:1320-1329.
97. Rothman RB, et al. Amphetamine-type central nervous system release of dopamine and serotonin. Synapse. 2001;39:32-41.
98. Itzhak Y, Martin J, Ali S. Methamphetamine-induced dopaminergic neurotoxicity in mice: long-lasting sensitization to the locomotor stimulation and desensitization to the rewarding effects of methamphetamine. Prog Neuropsychopharm Biol Psychiat. 2002;26:1177-1183.
99. Davidson C, Gow AJ, Lee TH, Ellinwood EH. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev. 2001;36:1-22.
100. Bennett B, Hollingsworth C, Martin R, Harp J. Methamphetamine-induced alterations in dopamine transporter function. Brain Res. 1998;782:219-227.
101. Yamamoto B, Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 1998;287:107-114.
102. Yamamoto B, Zhu W. Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys. J Pharmacol Exp Ther. 2006;316:1210-1218.
103. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther. 2004;311:1-7.
104. Reese EA, Bunzow JR, Arttamangkul S, Sonders MS, Grandy DK. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther. 2007;321:178-186.
105. Lewin AH. Receptors of mammalian trace amines. AAPS J. 2006;8:E138-E45.
106. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White J. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005;100:1320-1329.
107. Cook CE. Pyrolitic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine. In: Miller MA, Kozel NJ, editors. Methamphetamine Abuse: Epidemiologic Issues and implications. DHHS Pub. No. (ADM) 91-1836. NIDA. Rockville, MD; 1991. pp. 6-23.
108. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007;76:1169-1174.
109. Richards JR, Brofeldt BT. Patterns of tooth wear associated with methamphetamine use. J Peridontol. 2000;71:1371-1374.
110. Wagner GC, Carelli RM, Jarvis MF. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Pathol. Pharmacol. 1985;47:221-228.
111. Rothman RB, et al. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse. 2000;35:222-227.
112. Grabowski J, et al. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav. 2004;29:1439-1464.
113. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatr. 2008;165:1442-1448.
114. Marks DH. Cardiomyopathy due to ingestion of adderall. Am J Ther. 2008;15:287-289.
115. Freudenmann RW, Öxler F, Bernschneider-Reif S. The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006;101:1241-1245.
116. Benzenhöfer U, Passie T. The early history of "Ecstasy." (Article in German) Nervenarzt. 2006;77:95-99.
117. Shulgin A, Nichols D. Characterization of three new psychomimetics. In: Stillmann R, Wilette R, editors. The Psychopharmacology of Halluzinogens. New York: Pergamon; 1978. pp. 74-82.
118. Shulgin A. Pihkal: a chemical love story. Berkeley: Transform Press; 1995.
119. Greer G. Using MDMA in psychotherapy. Advances. 1985;2:57-59.
120. McGlothlin WH, Arnold DO. LSD revisited: a ten-year follow-up of the medical LSD use. Arch Gen Psychiatr. 1971;25:35-49.
121. Naranjo C. MDMA: the drug of analysis. New York: Ballantine Books; 1973.
122. Abramson HA. The use of LSD in psychotherapy and alcoholism. New York: Bobbs-Merrill; 1967.
123. Shulgin AT, Carter MF. Centrally active phenethylamines. Psychopharm Commun. 1974;1:93-98.
124. Margolis J. Ecstasy's dividend. Time. 2001;19:58-59.
125. Schmidt WJ, Mayerhofer A, Meyera A, Kovar KA. Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neurosci Lett. 2002;330:251-254.
126. Nair SG, Gudelsky GA. Protein kinase C inhibition differentially affects 3, 4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res. 2004;1013:168-173.
127. Homberg J, de Boer S, Raaso HS, Olivier JDA, Verheul M, Ronken E, et al. Adaptations in pre- and postsynaptic 5-HT1A receptor function and cocaine supersensitivity in serotonin transporter knockout rats. Psychopharmacology. 2008;200:367-380.
128. Mendelson J, editor. The Pharmacology of Ecstasy. MDMA/Ecstasy Research: Advances, Challenges and Future Directions; 2001; Bethesda, MD: US Goverment.
129. State RC, Grob CS, Poland RE, editors. Psychobiologic Effects of 3, 4-Methylenedioxymethamphetamine in Humans: A Pilot Study (Poster). MDMA/Ecstasy Research: Advances, Challenges and Future Directions; 2001; Bethesda, MD: US Goverment.
130. Gamma A, Buck A, Berthold T, Hell D, Vollenweider FX. 3, 4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy human. Neuropsychopharmacology. 2000;23:388-395.
131. Green AR, Mechan AO, Melliot JM, O'shea E, Colado MI. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). Pharmacol Rev. 2003;55:463-508.
132. Bankson MG, Cunningham KA. 3, 4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J Pharmacol Exp Ther. 2001;297:846-852.
133. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology. 2000;148:322-424.
134. Liechti ME, Geyer MA, Hell ID, Vollenweider FX. Effects of MDMA (Ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology. 2001;24:240-252.
135. Liester MB, Grob CS, Bravo GL, Walsh RN. Phenomenology and sequelae of 3, 4-methylenedioxymethamphetamine use. J Nerv Ment Dis. 1992;180:345-352.
136. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals: neurochemical and anatomical evidence. Science. 1985;229:986-988.
137. Lamers GTJ, Ramaekers JG, Muntjewerff ND, Sikkema KL, Riedel WJ, Samyn N, et al. Dissociable effects of a single dose of ecstasy (MDMA) on psychomotor skills and attentional performance. J Psychopharm. 2003;17:379-387.
138. Mathias R. "Ecstasy" damages the brain and impairs memory in humans. NIDA Notes. 1999;14:10-15.
139. Lester SJ, Baggott M, Welm S, Schiller NB, Jones RT, Foster E, et al. Cardiovascular effects of 3, 4-methylenedioxymethamphetamine: a double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:969-972.
140. Grob CS, Poland RE, Chang L, Ernst T. Psychobiologic effects of 3, 4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res. 1996;73:103-107.
141. Hall AP, Henry JA. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678-685.
142. Davis WM, Hatoum HT, Waters IW. Toxicity of MDA (3, 4- methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. Alcohol Drug Res. 1987;7:123-134.
143. Peroutka SJ, Pascoe N, Faull KF. Monoamine metabolites in the cerebrospinal fluid of recreational users of 3 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Res Commun Subst Abuse. 1987;8:125-138.
144. Ricaurte GA, Forno LS, Wilson MA, De Lanney L, Irwin I, Molliver ME, et al. (±) 3, 4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988;260:51-55.
145. Ricaurte GA, Matello AL, Katz JL, Martello MB. Long lasting effects of (±)-3, 4-methylenedioxyamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. J Pharmacol Exp Ther. 1992;261:616-622.
146. Reneman L, Booij J, den Heeten GJ, van den Brin W. Effects of MDMA (ecstasy) use and abstention on serotonin neurons. Lancet. 2002;359:1617-1618.
147. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science. 2002;297:2260-2263.
148. Grob CS. Decontructing ecstasy: the epolitics of MDMA research. Addict Res. 2000;6:549-588.
149. Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma J, Gunning B, et al. Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study - preliminary report. Psychopharmacology. 2002;159:335-340.
150. Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of parkinson disease. PLoS Biol. 2005;3:e271.
151. Morris K. Concern over research reawakens ecstasy neurotoxicity debate. Lancet. 2003;2:650.
152. Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, et al. Long-term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med. 2003;44:375-384.
153. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with MDMA seven years previously: factors influencing abnormal recovery. J Neurosci. 1999;19:5096-5107.
154. Hiramatsu M, Kumagai Y, Unger SE, Cho AK. Metabolism of methylenedioxymethamphetamine: formation of dihydroxy-methamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther. 1990;25:521-527.
155. Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151-1156.
156. Zhao ZY, Castagnoli NJ, Ricaurte GA, Steele T, Martello M. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3, 4-(methylenedioxy) phenyl] propane [(methylenedioxy)-methamphetamine]. Chem Res Toxocol. 1992;5:89-94.
157. Lim HK, Foltz RL. In vivo and in vitro metabolism of 3, 4-(methylenedioxy) methamphetamine in the rat: identification of metabolites using an ion trap detector. Chem Res Toxicol. 1988;1:370-378.
158. Wagner GC, Carelli RM, Jarvis MF. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology. 1086;25:559-561.
159. Bindoli A, Rigobello MP, Deeble DJ. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radical Biol Med. 1992;13:391-405.
160. Wagner G, Carelli R, Jarvis M. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res Commun Chem Path Pharm. 1985;47:221-228.
161. Leibovitz B. Phenethylamines, free radicals, and antioxidants. Multidiscip Ass Psychodel Stud. 1993;4:1-3.
162. McCann UD, Ricaurte CA. Reinforcing subjective effects of (±) 3, 4-methylenedioxymethaniphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence. J Clin Psychopharm. 1993;13:214-217.
163. Mas M, Farre M, de la Torre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999;290:136-145.
164. Cami J, de la Torre R, Ortuno J, et al. Pharmacokinetics of ecstasy (MDMA) in healthy subjects [abstr]. Eur J Clin Pharmacol. 1997;52:A168.
165. Verebey K, Alrazi J, Jaffee JH. The complications of 'Ecstasy' (MDMA). JAMA. 1988;259:1649-1650.
166. Helmlin HJ, Bracher K, Bourquin D, Vonlanthen D, Brenneisen R. Analysis of 3, 4-methylenedioxymeth-amphetamine (MDMA) and its metabolites in plasma and urine by HPLC-DAD and GC-MS. J Anal Toxicol. 1996;20:432-440.
167. Hiramatsu M, Di Stefano EW, Cho AK. Stereochemical differences in the in vivo and in vitro metabolism of MDMA [abstr]. FASEB. 1989;3:A1035.
168. Lin LY, Kumagai Y, Cho AK. Enzymatic and chemical demethylenation of (methylenedioxy) amphetamine and (methylenedioxy) methamphetamine by rat brain microsomes. Chem Res Toxicol. 1992;5:401-406.
169. de la Torre R, Farré M, Ortuno J, Mas M, Brenneisen R, Roset PN, et al. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br J Clin Pharmacol. 2000;49:104-109.
170. Lin LY, Di Stefano EW, Schmitz DA, et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos. 1997;25:1059-1064.
171. Kreth KP, Kovar KA, Schwab M, Zanger UM. Identification of the human cytochrome P450 involved in the oxidative metabolism of "Ecstasy"- related designer drugs. Biochem Pharmacol. 2000;59:1563-1571.
172. Schwab M, Seyringe RE, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet. 1999;353:593-594.
173. Saunders N. Ecstasy. In: Walder P, editor. Ecstasy und verwandte Designerdrogen. Zürich: Ricco Bilger; 1994. pp. 26-42.
174. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet. 1998;352:1751-1752.
175. Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy" - related drugs. Biochem Pharmacol. 2000;69:1563-1571.
176. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996;19:157-164.
177. Dar KJ, McBrien ME. MDMA-induced hyperthermia: report of a fatality and review of current therapy. Inten Care Med. 1996;22:995-996.
178. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3, 4-methylene-dioxymethamphetamine. Lancet. 1992;340:384-387.
179. Benowitz NL. Amphetamines. In: Olson KR, editor. Poisoning and drug overdose. Stamford, CT: Appleton & Lange; 1999. pp. 68-70.
180. Singarajah C, Lavies NG. An overdose of ecstasy: a role for dantrolene. Anaesthesia. 1992;47:686-687.
181. Mallick A, Bodenham AR. MDMA-induced hyperthermia: a survivor with an initial body temperature of 42.9°C. J Accid Emerg Med. 1997;14:336-338.
182. Murthy BVS, Wilkes RG, Roberts NB. Creatine kinase isoform changes following ecstasy overdose. Anaesth Inten Care. 1997;25:156-159.
183. Hall AP, Lyburn ID, Spears FD, Riley B. An unusual case of Ecstasy poisoning. Inten Care Med. 1996;22:670-671.
184. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology. 1998;19:241-251.
185. Hall AP. "Ecstasy" and the anaesthetist. Br J Anaesth. 1997;79:697-698.
186. Schmidt CJ, Black CK, Abbate GM, Taylor VL. MDMA-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 1990;529:85-90.
187. Olson KR. Comprehensive evaluation and treatment. In: Olson KR, editor. Poisoning and drug overdose. Stamford, CT: Appleton & Lange; 1999. pp. 1-61.
188. Ghuran A, Nolan J. Recreational drug misuse: issues for the cardiologist. Heart. 2000;83:627-633.
189. Qasim A, Townend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:E10.
190. Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with "Ecstasy" and "Eve" misuse. J Clin Pathol. 1996;49:149-153.
191. McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage and drug abuse in young adults. Br J Neurosurg. 2000;14:449-454.
192. Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol. 2002;21:1001-1007.
193. McCann U, Slate SO, Ricaurte GA. Adverse reactions with 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Drug Saf. 1996;15:107-115.
194. Ranalli E, Bouton R. Intracerebral haemorrhage associated with ingestion of "Ecstasy" [abstr]. Eur Neuropsychopharmacol. 1997;7:S263.
195. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking "Ecstasy". BMJ. 1993;307:1399.
196. Kessel B. Hyponatraemia after ingestion of "Ecstasy" BMJ. 1994;308:414.
197. Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after "Ecstasy" (3, 4-MDMA) [letter]. Lancet. 1996;347:1052.
198. Matthai SM, Davidson DC. Cerebral oedema after ingestion of MDMA ("Ecstasy") and unrestricted intake of water [letter]. BMJ. 1996;312:1359.
199. Henry JA, Fallon JK, Kicman AT, et al. Low-dose MDMA ("Ecstasy" ) induces vasopressin secretion [letter]. Lancet. 1998;351:1784.
200. Wilkins B. Cerebral oedema after MDMA ("Ecstasy") and unrestricted water intake: hyponatraemia must be treated with low water input. BMJ. 1999;313:689-690.
201. Parr MJA, Low HM, Botterill P. Hyponatremia and death after "Ecstasy" ingestion. Med J Aust. 1997;166:136-137.
202. Finch E, Sell L, Arnold D. Cerebral oedema after MDMA ("Ecstasy") and unrestricted water intake: drug workers emphasize that water is not an antidote to drug [letter]. BMJ. 1996;313:690.
203. Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, et al. The effect of 3, 4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol. 2002;135:649-656.
204. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3, 4-methylenedioxymethamphetamine ("ectasy"). Lancet. 1992;340:384-387.
205. Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut. 1996;38:454-458.
206. Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther. 1999;13:129-133.
207. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3, 4-methylenedioxymethamphetamine ('Ecstasy'). Br J Psychiatr. 1994;165:391-395.
208. Hayner GN, McKinney H. MDMA: the dark side of ecstasy. J Psychoactive Drugs. 1986;18:341-347.
209. Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy 'Ecstasy' (MDMA) polydrug users. Drug Alcohol Depend. 2000;60:105-110.
210. Dowling GP, McDonough ET, Bost RO. 'Eve' and 'Ecstasy': a report of five deaths associated with the use of MDEA and MDMA. JAMA. 1987;257:1615-1617.
211. Perrone J. Amphetamines. In: Viccellio P, editor. Emergency toxicology. Philadelphia: Lippincott-Raven; 1998. pp. 899-902.
212. Rochester JA, Kirchner JT. Ecstasy (3, 4-methylene-dioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract. 1999;12:137-142.
213. Screaton GR, Singer M, Cairns HS, Thrasher A, Sarne RM, Cohen SL. Hyperpyrexia and rhabdomyolysis after MDMA ("Ecstasy") abuse [letter]. Lancet. 1992;339:677-678.
214. McKinney PE. Designer drugs. In: Haddad LM, Shannon MW, Winchester JF, editors. Poisoning and drug overdose. Philadelphia: WB Saunders; 1998. pp. 569-580.
215. Ames D, Wirshing WC. Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome - a possible link. J Am Med Assoc. 1992;268:1505-1506.
216. Tehan B. Tehan B. Ecstasy and dantrolene [letter]. BMJ. 1993;306:146.
217. Logan AS, Stickle B, O'Keefe N. Survival following "Ecstasy" ingestion with a peak temperature of 42 degrees. Anaesthesia. 1993;48:1017-1018.
218. Larner AJ. Dantrolene and 'Ecstasy' overdose. Anaesthesia. 1993;38:179-180.
219. Singarajah C, Lavies NG. An overdose of ectasay. A role for dantrolene. Anaesthesia. 1992;47:686-687.
220. Campkin NTA, Davies UM. Treatment of 'Ecstasy' overdose with dantrolene [letter]. Anaesthesia. 1993;48:82-83.
221. Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH. Exceptional heatstroke induced by amphetamine analogues - does dantrolene have a place. Anaesthesia. 1993;48:542-543.
222. Dowsett RP. Deaths attributed to "Ecstasy" overdose [letter]. Med J Aust. 1996;164:700.
223. Chadwick IS, Curry PD, Linsley A, Freemont AJ, Doran B. Ecstasy, 3, 4-methylenendioxyamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia [letter]. J R Soc Med. 1991;84:371.
224. Hopkins PM, Ellis FR, Halsall PJ. Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet. 1991;338:1491-1492.
225. Hollander JE. The management of cocaine-associated myocardial ischemia. N Engl J Med. 1995;333:1267-1272.
226. Sandyk R. L-dopa induced 'serotonin syndrome' in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol. 1986;6:194-195.
227. Guze BH, Baxter LRJ. The serotonin syndrome: case responsive to propranolol [letter]. J Clin Psychopharmacol. 1986;6:119-120.
228. McDowell DM. MDMA, ketamine, GHB, and the "club drug" scene. In: Galanter M, Kleber HD, editors. Textbook of substance abuse treatment. Washington, DC: American Psychiatric Press; 1999. pp. 295-305.
229. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA or "Ecstasy") . Psychopharmacology. 1995;119:247-60.
230. Ashgar K, De Souza E. Pharmacology and Toxicology of Amphetamine and Related Designer Drugs. Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration; 1989.
231. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-80.
232. Langston JW, Irwin I, Langston EB, Forno LS. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 1984;225:1480-2.
233. Shulgin A, Shulgin A. Pihkal: a chemical love story. Berkeley, CA: Transform Press; 1995.
234. Shulgin A, Shulgin A. Thikal: the continuation. Berkeley, CA: Transform Press; 1997.
235. Tunnicliff G. Significance of g-hydroxybutyric acid in the brain. Gen Pharmacol. 1992;23:1027-34.
236. Castelli MP, Ferraro L, Mocci I, Carta F, Carai MA, Antonelli T, et al. Selective gammahydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J Neurochem. 2000;87:722-32.
237. Spanos PF, Tagliamonte A, Tagliamonte P, Gessa GL. Stimulation of brain dopamine synthesis by g-hydroxybutyrate. J Neurochem. 1971;18:1831-6.
238. Feigenbaum JJ, Howard SG. Does gamma-hydroxybutyrate inhibit or stimulate central DA release? Int J Neurosci. 1996;88:53-69.
239. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB) - a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35:581-90.
240. Andriamampandry C, Taleb O, Viry S, Muller C, Humbert J, Gobaille S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma hydroxybutyrate (GHB). FASEB. 2003;17:1691-3.
241. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res. 1992;572:345-8.
242. Colombo G, Agabio R, Bourguignon J, Faddo F, Cobina C, Maitre M, et al. Blockade of the discriminative stimulus effects of gamma-hydroxybutytic acid (GHB) by the GHB receptor autagonist NCS-382. Physiol Behav. 1995;58:587-590.
243. Laborit H. Sodium 4-hydroxybutyrate. Int J Neuropharmacol. 1964;3:433-52.
244. Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature. 1963;200:1207-8.
245. Root B. Oral premedication of children with 4-hydroxybutyrate. Anesthesiology. 1965;26:259-60.
246. Winters WD, Spooner CE. Various seizure activities following gamma-hydroxybutyrate. Int J Neuropharmacol. 1965;4:197-200.
247. Godschalk M, Dzoljic MR, Bonta IL. Slow wave sleep and a state resembling absence epilepsy induced in the rat by g-hydroxybutyrate. Eur J Pharmacol. 1977;44:105-11.
248. Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg. 1965;44:532-9.
249. Mamelak M, Scharf MB, Woods M. Treatment of narcolepsy with gamma-hydroxybutyrate: a review of clinical and sleep laboratory findings. Sleep. 1986;9:285-9.
250. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab. 1977;44:1014-7.
251. Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet. 1989;2:787-9.
252. Gallimberti L, Cibin M, Pagnin P, et al. Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome. Neuropsychopharmacology. 1993;9:77-81.
253. WHO questionnaire for review of dependence-producing psychoactive substances, 2000.
254. Sanguineti VR, Angelo A, Frank MR. GHB: a home brew. Am J Drug Alcohol Abuse. 1997;23:634-42.
255. Wiley J, Dick R, Arnold T. Hematuria from home-manufactured GHB. J Toxicol Clin Toxicol. 1998;46:502-3.
256. Henretig F, Vassalluzo C, Osterhoudt K, et al. "Rave by net": gamma-hydroxybutyrate (GHB) toxicity from kits sold to minors via the internet [abstr]. J Toxicol Clin Toxicol. 1998;36:503.
257. Palatini P, Tedeschi L, Frison G, et al. Dose-dependent absorption and elimination of gammahydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45:353-6.
258. Ferrara SD, Zotti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol. 1992;34:231-5.
259. Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep. 1998;21:507-14.
260. Helrich M, McAslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology. 1964;25:771-5.
261. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Encephale. 1980;6:93-9.
262. Vickers MD. Gamma-hydroxybutyric acid. Int Anesthesiol Clin. 1969;7:75-89.
263. Lettieri J, Fung H. Absorption and first-pass metabolism of (14) C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol. 1976;13:435-7.
264. Roth RH, Giarman NJ. Conversion in vivo of gamma-aminobutyric to g-hydroxybutyric acid in the rat. Biochem Pharmacol. 1969;18:247-50.
265. Cash CD. Gamma-hydroxybutyrate: an overview of the pros and cons for it being a neurotransmitter and/or a useful therapeutic agent. Neurosci Biobehav Rev. 1994;18:291-304.
266. Mandel P, Maitre M, Vayer P, Hechler V. Function of -hydroxybutyrate: a putative neurotransmitter. Biochem Soc Trans. 1987;15:215-7.
267. Vayer P, Mandel P, Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci. 1987;41:1547-58.
268. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol. 1992;23:1027-34.
269. Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB): a neuroactive drug with abuse potential. J Toxicol Clin Toxicol. 1997;35:581-90.
270. Anderson RA, Ritzmann RF, Tabakoff B. Formation of gamma-hydroxybutyrate in brain. J Neurochem. 1977;28:633-9.
271. Doherty JD, Roth RH. Metabolism of gamma-hydroxy-[1-14C] butyrate by rat brain: relationship to the Krebs cycle and metabolic compartmentation of amino acids. J Neurochem. 1978;30:1305-9.
272. Roth RH, Doherty JD, Walters JR. Gamma-hydroxybutyrate: a role in the regulation of central dopaminergic neurons ? Brain Res. 1980;189:556-60.
273. Vayer P, Ehrhardt J, Gobaille S, Mandel P, Maitre M. Gamma- hydroxybutyrate distribution and turnover rates in discrete brain regions of the rat. Neurochem Int. 1988;12:53-9.
274. Benavides J, Rumigny J, Bourguignon JJ, et al. High-affinity binding site for gammahydroxybutyric acid in rat brain. Life Sci. 1982;30:953-61.
275. Hechler V, Bourguignon JJ, Wermuth CG, Mandel P, Maitre M. Gamma-hydroxybutyrate uptake by rat brain striatal slices. Neurochem Res. 1985;10:387-96.
276. Nelson T, Kaufman E, Kline J, Sokoloff L. The extraneural distribution of g-hydroxybutyrate. J Neurochem. 1981;37:1345-8.
277. Vayer P, Maitre M. Gamma-hydroxybutyrate stimulation of the formation of cyclic GMP and inositol phosphates in rat hippocampal slices. J Neurochem. 1989;52:1382-7.
278. Maitre M, Hechler V, Vayer P, et al. A specific gamma-hydroxybutyrate receptor ligand possesses both antagonistic and anticonvulsant properties. J Pharmacol Expt Ther. 1990;255:657-63.
279. Bernasconi R, Lauber J, Marescaux C, et al. Experimental absence seizures: potential role of g-hydroxybutyric acid and GABAB receptors. J Neural Transm Suppl. 1992;35:155-77.
280. Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurones by activating GABAB receptors. Eur J Pharmacol. 1992;219:292-4.
281. Serra M, Sanna E, Foddi C, Concas A, Biggio G. Failure of gamma-hydroxybutyrate to alter the function of the GABAA receptor complex in the rat cerebral cortex. Psychopharmacology. 1991;104:351-5.
282. Gessa GL, Vargiu L, Crabai F, Boero GC, Caboni F, Camba R. Selective increase of brain dopamine induced by gamma-hydroxybutyrate. Life Sci. 1966;5:1921-30.
283. Bustos G, Roth RH. Effect of gamma-hydroxybutyrate on the release of monoamines from the rat striatum. Br J Pharmacol. 1972;44:817-20.
284. Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gammahydroxybutyrate in striatum: a microdialysis study. J Neurochem. 1991;56:938-44.
285. Snead OCI, Bearden LJ. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate. Neurology. 1980;30:832-8.
286. Grove-White IG, Kelman GR. Effect of methohexitone, diazepam and sodium 4-hydroxybutyrate on short-term memory. Br J Anaesth. 1971;43:113-6.
287. Mamelak M, Sowden K. The effect of gamma-hydroxybutyrate on the H-reflex: pilot study. Neurology. 1983;33:1497-14500.
288. Lapierre O, Lamarre M, Montplaisir J, Lapierre G. The effect of g-hydroxybutyrate: a doubleblind study of normal subjects [abstr]. Sleep Res. 1988;17:99.
289. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroenceph Clin Neurophysiol. 1966;20:506-12.
290. Prevention CfDCa. Multistate outbreak of poisonings associated with illicit use of g-hydroxybutyrate. MMWR. 1990;39:861-3.
291. Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma-hydroxybutyrate in man. Can Anaesth Soc J. 1966;13:119-23.
292. Appleton PJ, Burn JM. A neuroinhibitory substance: gamma-hydroxybutyric acid. Anseth Analg. 1968;47:164-70.
293. Van Cauter E, Plat L, Scharf MB, Leproult R, Cespedes S, L'Hermite-Baleriaux M. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxy-butyrate in normal young men. J Clin Invest. 1997;100:745-53.
294. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurolo Sci. 1980;7:23-31.
295. Scrima L, Hartman PG, Johnson FHJ, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990;13:479-90.
296. Scharf MB, Brown D, Woods M, Brown L, Hirschowitz J. The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry. 1985;46:222-5.
297. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurolo Sci. 1980;7:23-31.
298. Lapierre O, Montplaisir J, Lamarre M, Bedard MA. The effect of gamma-hydroxybutyrate on nocturnal and diurnal sleep of normal subjects: further considerations on REM sleep-triggering mechanisms. Sleep. 1990;13:24-39.
299. Entholzner E, Mielke L, Pichlmeier R, Weber F, Schneck H. EEG changes during sedation with g-hydroxybutyric acid. Anaesthesist. 1995;44:345-50.
300. Kleinschmidt S, Schellhase C, Mertzlufft F. Continuous sedation during spinal anaesthesia: gamma-hydroxybutyrate vs propofol. Eur J Anaesthesiol. 1999;16:23-30.
301. Mamelak M. Gamma-hydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev. 1989;13:187-98.
302. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of g-hydroxybutyric acid with recommendations for management. Ann Emerg Med. 1998;31:729-36.
303. Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gammahydroxybutyrate. Can J Neurol Sci. 1979;6:1-6.
304. Gessa GL, Addolorato G, Caputo F, et al. Symposium on gamma-hydroxybutyric acid (GHB): a neurotransmitter, a medicine, a drug of abuse. Alcohol. 2000;20:213-304.
305. Addolorato G, Caputo F, Stefanini GF, Gasbarrini G. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: possible craving development for the drug. Addiction. 1997;92:1035-6.
306. Bessman SP, Rossen J, Layne EC. Gamma-aminobutyric acid-glutamic acid transamination in brain. J Biol Chem. 1953;201:385-91.
307. Fishbein WN, Bessman SP. Gamma-hydroxybutyrate in mammalian brain. Reversible oxidation by lactic dehydrogenase. J Biol Chem. 1964;239:357-61.
308. Nelson T, Kaufman EE. Developmental time courses in the brain and kidney of two enzymes that oxidize-hydroxybutyrate. Dev Neurosci. 1994;16:352-8.
309. Dyer JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizure-like activity. Am J Emerg Med. 1991;9:321-4.
310. Galloway GP, Frederick SL, Staggers FEJ, Gonzales M, Stalcup SA, Smith DE. Gammahydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction. 1997;92:89-96.
311. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med. 1992;156:380-4.
312. McDowell DM. MDMA, ketamine, GHB, and the "club drug" scene. In: Galanter M, Kleber HD, editors. Textbook of substance abuse treatment. Washington, DC: American Psychiatric Press; 1999. pp. 295-305.
313. McCabe ER, Layne EC, Sayler DF, Slusher N, Bessman SP. Synergy of ethanol and a natural soporific: gamma-hydroxybutyrate. Science. 1971;171:404-6.
314. Gerra G, Caccavari R, Fontanesi B, et al. Flumazenil effects on growth hormone response to g-hydroxybutyric acid. Int Clin Psychopharmacol. 1994;9:211-5.
315. Addolorato G, Capristo E, Gessa GL, Caputo F, Stefanini GF, Gasbarrini G. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sci. 1999;65:191-5.
316. Centers for Disease Control and Prevention. Multistate outbreak of poisonings associated with illicit use of gamma-hydroxybutyrate. MMWR. 1990;39:861-3.
317. Centers for Disease Control and Prevention. Gamma-hydroxybutyrate use: New York and Texas, 1995-1996. MMWR. 1997;46:281-3.
318. Ross TM. Gamma-hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous drug. J Emerg Nurs. 1995;21:374-6.
319. Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GHB or "Liquid Ecstasy"): a case report. BMJ. 1997;314:35-6.
320. Steele MT, Watson WA. Acute poisoning from gamma-hydroxybutyrate (GHB). Mol Med. 1995;92:354-47.
321. Libetta C. Gamma-hydroxybutyrate poisoning. J Accid Emerg Med. 1997;14:411-2.
322. Ryan JM, Stell I. Gamma-hydroxybutyrate: a coma-inducing recreational drug. J Accid Emerg Med. 1997;14:259-61.
323. Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med. 1998;31:716-22.
324. Viera AJ, Yates SW. Toxic ingestion of gamma-hydroxybutyric acid. South Med J. 1999;92:404-5.
325. Louagie HK, Verstraete AG, De Soete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined in-take of g-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol. 1997;35:591-4.
326. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med. 1998;31:723-8.
327. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med. 2000;19:47-50.
328. Food and Drug Administration. FDA warns about products containing gamma-butyrolactone or GBL and asks companies to issue a recall. Rockville, MD: National Press Office; 1999.
329. Garrison G, Muller P. Clinical features and outcomes after unintentional gamma-hydroxybutyrate (GHB) overdose [abstr]. J Toxicol Clin Toxicol. 1998;36:503-4.
330. Louagie HK, Verstraete AG, De Soete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined in-take of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol. 1997;35:591-4.
331. Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. J Forensic Sci. 1995;40:501-4.
332. Fieler EL, Coleman DE, Baselt RC. Gamma-hydroxybutyrate concentrations in pre- and postmortem blood and urine. Clin Chem. 1998;44:692-3.
333. Timby N, Eriksson A, Bostrom K. Gamma-hydroxybutyrate-associated deaths. Am J Med. 2000;108:418-519.
334. Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc. 2000;75:401-2.
335. Hodges B, Everett J. Acute toxicity from home-brewed gamma- hydroxybutyrate. J Am Board Fam Pract. 1998;11:154-7.
336. Brown TC. Gamma-hydroxybutyrate in pediatric anaesthesia. Aust N Z J Surg. 1970;40:94-9.
337. Dyer JE, Reed JH. Alkali burns from illicit manufacture of GHB [abstr]. J Toxicol Clin Toxicol. 1997;35:553.
338. Galloway GP, Frederick SL, Staggers J. Physical dependence on sodium oxybate [letter]. Lancet. 1993;343:57.
339. Dyer JE, Andrews KM. Gamma-hydroxybutyrate withdrawal [abstr]. J Toxicol Clin Toxicol. 1997;35:553.
340. Dyer JE, Roth B, Hyma BA. GHB withdrawal syndrome: eight cases [abstr]. J Toxicol Clin Toxicol. 1999;37:650.
341. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med. 2000;18:65-70.
342. Friedman J, Westlake R, Furman M. "Grievous bodily harm": gammaq-hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology. 1996;46:469-71.
343. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med. 1998;31:729-36.
344. Harraway T, Stephenson L. Gamma-hydroxybutyrate intoxication: the gold coast experience. Emerg Med. 1999;11:45-8.
345. Badcock NR, Zotti R. Rapid screening test for gamma-hydroxybutyric acid (GHB, Fantasy) in urine [letter]. Ther Drug Monit. 1999;21:376.
346. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA. Adverse events, including death, associated with the use of 1, 4-butanediol. N Engl J Med. 2001;344:87-94.
347. Marwick C. Coma-inducing drug GHB may be reclassified. JAMA. 1997;277:1505-6.
348. Dyer JE. Gamma-hydroxybutyrate (GHB). In: Olson KR, editor. Poisoning and drug overdose. Stamford, CT: Appleton & Lange; 1999. pp. 179-81.
349. Henderson RS, Holmes CM. Reversal of the anaesthetic action of sodium gamma-hydroxybutyrate. Anaesth Intensive Care. 1976;4:351-4.
350. Lelkens JP. A simple, cheap, effective and safe procedure for general anesthesia. Acta Anaesthesiol Belg. 1976;27:25-34.
351. Holmes CM, Henderson RS. The elimination of pollution by a noninhalational technique. Anaesth Intensive Care. 1978;6:120-4.
352. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, et al. Collapse, reported seizure - and an unexpected pill. Lancet. 2007;369:1411-3.
353. White R, Standen O. Piperazine in the treatment of threadworms in children; report on a clinical trial. Br Med J. 1953;2:755-8.
354. Standen O. Activity of piperazine, in vitro, against Ascaris lumbricoides. Br Med J. 1955;2:20-2.
355. Campbell H, Cline W, Evans M, Lloyd J, Peck A. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol. 1973;6:170-6.
356. Gee P, Fountain J. Party on BZP party pills in New Zealand. N Z Med J. 2007;120:u2422.
357. Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J. 2006;119:U1959.
358. Baumann M, Clark R, Budzynski A, Partilla J, Blough B, Rothman R. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci. 2006;1025:189-97.
359. Tekes K, Tóthfalusi L, Malomvölgyi B, Hermán F, Magyar K. Studies on the biochemical mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm. 2007;30:203-11.
360. Lyon R, Titeler M, McKenney J, Magee P, Glennon R. Synthesis and evaluation of phenyl- and benzylpiperazines as potential serotonergic agents. J Med Chem. 1986;29:630-4.
361. Brennan KA, Lake B, Hely L, H. S., Jones K, K., Gittings D, Colussi-Mas J, et al. N-Benzylpiperazine has characteristics of a drug of abuse. Behav Pharmacol. 2007;18:785-90.
362. Brennan K, Johnstone A, Fitzmaurice P, Lea R, Schenk S. Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend. 2007;88:204-13.
363. Preissel U, Preissel HG. Brugmansia and Datura: Angel's Trumpets and Thorn Apples. Buffalo, NY: Firefly Books; 2002. pp. 106-129.
364. van Wyk BE. Handbuch der Arzneipflanzen. Stuttgart: Wissnschaftliche Verlagsgesllschaft; 2004.
365. Barker SA, Monti JA, Christian ST. N, N-Dimethyltryptamine: an endogenous hallucinogen. Rev Neurobiol. 1981;22:83-110.
366. Biocca EF, Galeffi C, Montalvo EG, Marini-Bettòlo GB. Sulla sostanze allucinogene impiegata in Amazzonia. Nota 1. Osservazioni sul paricà dei Tukfino e TariSna del bacino del Rio Uaupds. Annali di Chimica. 1964;54:1175-8.
367. Ott J. Pharmahuasca: human pharmacology of oral DMT plus harmine. J Psychoact Drugs. 1999;31:171-7.
368. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for adverse interaction. J Psychoact Drugs. 1998;30:367-9.
369. Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357-64.
370. Fischer R, England SM, Archer RC, Dean RK. Psilocybin reactivity and time contraction as measured by psychomotor performance. Drug Res/ Arzneimittelforsch. 1966;16:180-5.
371. Wittmann M, Carter O, Hasler F, et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J Psychopharmacol. 2007;21:50-64.
372. Wackermann J, Wittmann M, Hasler F, Vollenweider FX. Effects of varied doses of psilocybin on time interval reproduction in human subjects. Nuerosci Lett. 2008;435:51-5.
373. Griffiths R, Richards W, Johnson M, McCann U, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22:621-32.
374. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacology. 2008;115:9-14.
375. Popik P, Skolnick P. Pharmacology of ibogaine and ibogaine-related alkaloids. In: Cordell GA, editor. The alkaloids. San Diego, CA: Academic; 1998. pp. 179-231.
376. Alper KR. Ibogaine: A review. In: Alper KR, editor. The alkaloids. San Diego, CA: Academic; 2001. pp. 1-38.
377. Alper KR, Lotsof HS, Frenken GMN, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Drug Addict. 1999;8:234-42.
378. Mash DC, Kovera CA, Pablo J, Tyndale RF, Erwin FD, Williams IC, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Neurobiological Mechanisms of Drugs of Abuse 2000. pp. 394-401.
379. Glick SD, et al. (±)-18-Methoxycoronaridine: a novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Rev. 1999;5:27-42.
380. Helsley S, Fiorella D, Rabin RA, Winter JC. Behavioral and biochemical evidence for a nonessential 5-HT2A component of the ibogaine-induced discriminative stimulus. Pharmacol Biochem Behav. 1998;59:419-25.
381. Mach RH, Smith CR, Childers SR. Ibogaine possesses a selective affinity for sigma 2 receptors. Life Sci. 1995;57:PL57-62.
382. Maciulaitis R, Kontrimaviciute V, Bressolle F, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human Exp Toxicol. 2008;27:181-94.
383. Nichols DE. Hallucinogens. Pharmacol Ther. 2004;101:131-81.
384. Monte AP, Waldman SR, Marona-Lewicka D, et al. Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives. J Med Chem. 1997;40:2997-3008.
385. Diaz J. How drugs influence behavior. Englewood Cliffs, NJ\Prentice Hall; 1996.
386. Perrine DM. Hallucinogens and obsessive-compulsive disorder. Am J Psychiatry. 1999;156:1123.
387. Buckholtz NS, Zhou DF, Freedman DX, Potter WZ. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin 2 receptors in rat brain. Neuropsychopharmacology. 1990;3:137-48.
388. Sewell RA, et al. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66:1920-2.
389. Schnoll SH, Weaver MF. Addiction and pain. Am J Addict. 2003:S27-S35.
390. National Center on Addiction and Substance Abuse Missed Opportunity: Columbia University, New York CASA National Survey of Primary Care Physicians and Patients on Substance Abuse; 2000.
391. Cherny NI. Opioid analgesics. Comparative features and prescribing guidelines. Drugs. 1996;51:714-737.
392. Cami J, Farré M. Drug addiction - mechanisms of disease. N Engl J Med. 2003;349:975-86.
393. McLellan AT, et al. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-1695.
394. Kendler KS, et al. Illicit psychoactive substance use, heavy use, abuse, and dependence in a US population-based sample of male twins. Arch Gen Psychiat. 2000;57:261-269.
395. Jacob T, et al. Genetic and environmental effects on offspring alcoholism. New insights using an offspring-of-twins design. Arch Gen Psychiat. 2003;60:1265-1272.
396. Kreek MJ, Nielson DA, La Forge KS. Genes associated with addiction: alcoholism, opiate, and cocaine addiction. Neuromol Med. 2004;5:85-108.
397. Koob GF, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27:739-749.
398. Simpson D, et al. Screening for drugs of abuse (II): cannabinoids, lysergic acid diethylamide, buprenorphine, methadone, barbiturates, benzodiazepines and other drugs. Ann Clin Biochem. 1997;34:460-510.
399. Wolff K, et al. A review of biological indicators of illicit drug use, practical considerations and clinical usefulness. Addiction. 1999;94:1279-1298.
400. Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. In: Goodman & Gilman's the Pharmacological Basis of Therapeutics. 9th edition New York: McGraw-Hill; 1996.
401. Girault JA, Greengard P. The neurobiology of dopamine signaling. Arch Neurol. 2004;61:641-644.
402. Freye E, Levy JV. Opioids in Medicine - A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States. Dordrecht, The Netherlands: Springer Science + Business Media BV; 2008.
403. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manag. 1996;11:203-217.
404. Weaver MF, Jarvis MAE, Schnoll SH. Role of the primary care physician in problems of substance abuse. Arch Intern Med. 1999;159:913-924.
405. Miotto K, et al. Diagnosing addictive disease in chronic pain patients. Psychosomatics. 1996;37:223-235.
406. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain. 2002;18:S28-S38.
407. Compton P, Darakjian K, Miotto K. Screening for addiction in patients with chronic pain and "problematic" substance use: evaluation of a pilot assessment tool. J Pain Symptom Manag. 1996;16:355-363.
408. Smith KE, Fenske NA. Cutaneous manifestations of alcohol abuse. J Am Acad Dermatol. 2000;43:1-16.
409. Fiellin DA, Reid MC, O'Connor PG. Outpatient management of patients with alcohol problems. Ann Intern Med. 2000;133:85-827.
410. Skinner HA, et al. Identification of alcohol abuse using laboratory tests and a history of trauma. Ann Intern Med. 1984;101:847-851.
411. Ewing J. Detecting alcoholism: the CAGE questionnaire. JAMA. 1984;252:1905-1907.
412. Minovitz O, Driol M. The sexual abuse, eating disorder and addiction (SEA) triad: syndrome or coincidence ? Med Law. 1989;8:59-61.
413. Vastag B. What's the connection? No easy answers for people with eating disorders and drug abuse. JAMA. 2001;285:1006-1007.
414. Bastiaens L, Francis G, Lewis K. The RAFFT as a screening tool for adolescent substance use disorders. Am J Addict. 2000;9:10-16.
415. Knight JR, et al. Validity of the CRAFFT substance abuse screening test among adolescent clinic patients. Arch Pediatr Adolesc Med. 2002;156:607-614.
416. Sillanaukee P, Olsson U. Improved diagnostic classification of alcohol abusers by combining carbohydrate-deficient transferrin and gamma- glutamyltransferase. Clin Chem. 2001;47:681-685.
417. Papoz L, et al. Alcohol consumption in a healthy population. Relationship to gamma-glutamyl transferase activity and mean corpuscular volume. JAMA. 1981;245:1748-1751.
418. Freye E, Levy JV. Detection of illicit use of opioids in primary care. In: Freye E, Levy J V, editors. Opioids in Medicine - A Comprehensive Review on the Mode of Action and the Use of Analgesics in Different Clinical Pain States. Dordrecht, The Netherlands: Springer Science + Business Media BV; 2008. pp. 412-465.
419. Hammett-Stabler C, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clinica Chimica Acta. 2002;315:125-135.
420. Galloway JH, Marsh ID. Detection of drug misuse - an addictive challenge. J Clin Pathol. 1999;52:713-718.
421. Shults TS. Medical Review Officer's Handbook. North Carolina: Research Triangle Park; 2002.
422. Gourlay DL. Urine Drug Testing in Clinical Practice: Dispelling the Myths & Designing Strategies: Monograph; 2004.
423. Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clinica Belgica. 2000;55:323-333.
424. Casavant MJ. Urine drug screening in adolescents. Pediatr Clin N Am. 2002;49:317-327.
425. Hattab EM, et al. Modification of screening immunoassays to detect sub-threshold concentrations of cocaine, cannabinoids, and opiates in urine: use for detecting maternal and neonatal drug exposure. Ann Clin Lab Sci. 2000;30:85-91.
426. Braithwaite RA, et al. Screening for drugs of abuse. I: opiates, amphetamines and cocaine. Ann Clin Biochem. 1995;32:123-153.
427. Cook JD, et al. The characterization of human urine for specimen validity determination in workplace drug testing: a review. J Anal Toxicol. 2000;24:579-588.
428. Perrone J, et al. Drug screening versus history in detection of substance use in ED psychiatric patients. Am J Emerg Med. 2001;19:49-51.
429. Oyler JM, et al. Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000;24:530-535.
430. Cunningham JK, Liu LM. Impacts of Federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction. 2003;98:1220-1237.
431. ® (pantoprazile sodium) package insert 2004.
432. ®; Product Information. In: Arky R, editor. Physicians' Desk Reference (PDR). Montvale, NJ: Medical Economics; 1989. pp. 2544-2546.
433. Bosy TZ, Cole BA. Consumption and quantitation of 9-tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol. 2000;24:562-566.
434. Leson G, et al. Evaluating the impact of hemp food consumption on workplace drug tests. J Anal Toxicol. 2001;25:691-698.
435. Baden LR, et al. Quinolones and false-positive urine screening for opiates by immunoassay technology. JAMA. 2001;286:3115-3119.
436. Zacher JL, Givone DM. False-positive urine opiate screening associated with fluoroquinolone use. Ann Pharmacother. 2004;38:1525-1528.
437. Caplan YH, Goldberger BA. Alternative specimens for workplace drug testing. J Anal Toxicol. 2001;25:396-399.
438. Kintz P, Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit. 2002;24:239-246.
439. Yacoubian GSJ, Wish ED, Pérez DM. A comparison of saliva testing to urinalysis in an arrestee population. J Psychoactive Drugs. 2001;33:289-294.